Vetter: multi-year project to fulfill ‘need for increased downstream resources’

By Melissa Fassbender contact

- Last updated on GMT

Vetter VSP facility in Ravensburg. (Image: Vetter Pharma International GmbH)
Vetter VSP facility in Ravensburg. (Image: Vetter Pharma International GmbH)
Vetter has begun an expansion of its secondary packaging capacities that will increase its facility by approximately 32,000 square feet.

The expansion is taking place at the contract development and manufacturing organization’s (CDMO) Ravensburg, Germany-based facility.

Based on our continuous growth in development support and aseptic manufacturing capacity, we have identified the need for increased downstream resources, such as secondary packaging capacity​,” Markus Kirchner, corporate spokesperson, Vetter Pharma International GmbH, told Outsourcing-Pharma.comm.

Hand in hand with the ever-increasing complexity of the development, manufacturing, and assembly/packaging processes in the injectable business segment, customers are asking for integrated solutions at their strategic CDMO partners,​” he added.

The expansion is expected to be completed over the next several years and will include new fully-automated packaging lines as well as space for manual and semi-automated packaging processes.

Assembly equipment for a variety of formats will also be included, such as for pens and autoinjectors.

The company will also expand its serialization and aggregation service.

The investment strategy

The German CDMO announced a €300m investment ($335m) in September 2015​ to overhaul its manufacturing network. As part of this strategy, the company has made several expansions​ at the Ravensburg site, which will replace its Holbeinstrasse site.

Approximately 800 employees will be migrated​ to the Ravensburg site by the end of the year.

A new administration building​ is expected to be completed by mid-year 2019. 

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars